A phase 2 study showed a 93.3% objective response rate for lenvatinib and tislelizumab in FH-RCC patients, with a 20% complete response rate. FH-RCC is driven by FH gene mutations, leading to early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback